Aphios
Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.
Industries
Nr. of Employees
small (1-50)
Aphios
Patents
Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
2020-11-10 • US-10828276-B2
View Details
Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
2020-11-10 • US-10828276-B2
View DetailsProducts
Enhanced ginger formulation for chemotherapy-associated nausea and vomiting (adjunctive therapy)
An enhanced natural-product formulation developed for chemotherapy-induced nausea and vomiting (CINV) with clinical evaluation in randomized multicenter trials.
PKC-activator therapeutic for neurodegenerative disease (intravenous and oral reformulations)
A small-molecule PKC modulator developed for amelioration of Alzheimer’s disease pathophysiology with intravenous clinical evaluation and reformulation efforts for oral administration using nanoparticle-based delivery methods.
Combination HIV-latency nanotherapeutic (co-encapsulated latency reversal agents)
A nanoparticle formulation co-encapsulating a protein kinase C modulator and a histone deacetylase inhibitor designed to reactivate latent HIV reservoirs for clearance.
Sustained-release cannabidiol (CBD) nanoparticles for opioid relapse prevention
Biodegradable polymer nanoparticle formulation of cannabidiol designed for sustained release to reduce opioid cravings and withdrawal-related behaviors (NIH SBIR-funded development).
Enhanced ginger formulation for chemotherapy-associated nausea and vomiting (adjunctive therapy)
An enhanced natural-product formulation developed for chemotherapy-induced nausea and vomiting (CINV) with clinical evaluation in randomized multicenter trials.
PKC-activator therapeutic for neurodegenerative disease (intravenous and oral reformulations)
A small-molecule PKC modulator developed for amelioration of Alzheimer’s disease pathophysiology with intravenous clinical evaluation and reformulation efforts for oral administration using nanoparticle-based delivery methods.
Combination HIV-latency nanotherapeutic (co-encapsulated latency reversal agents)
A nanoparticle formulation co-encapsulating a protein kinase C modulator and a histone deacetylase inhibitor designed to reactivate latent HIV reservoirs for clearance.
Sustained-release cannabidiol (CBD) nanoparticles for opioid relapse prevention
Biodegradable polymer nanoparticle formulation of cannabidiol designed for sustained release to reduce opioid cravings and withdrawal-related behaviors (NIH SBIR-funded development).
Expertise Areas
- Nanotechnology drug delivery
- Preclinical animal models and efficacy testing
- Clinical trial design and execution (Phase II–III)
- Formulation development and CMC for oral and intravenous routes
Key Technologies
- Phospholipid-based nanoparticle systems
- Biodegradable polymer nanoparticle formulations
- Surface modification for long-circulating nanoparticles (e.g., PEGylation)
- Co-encapsulation (multi-drug nanoparticle delivery)